Study on new ED drugs

[Flavio]

Here's a study on emerging ED drugs that mentions Zoraxel (clavulanic acid):


Beyond the Abstract - The future is today: Emerging drugs for the treatment of erectile dysfunction, by Maarten Albersen, MD


Wednesday, 21 July 2010
BERKELEY, CA (UroToday.com) - Erectile Dysfunction (ED) is the most common male sexual dysfunction presented for treatment, and the most thoroughly studied sexual dysfunction in men. In the late 20th century, important discoveries were made regarding both the physiologic processes of penile erection and the pathophysiology of ED. These discoveries led to the commercial introduction of the phosphodiesterase type 5 inhibitors (PDE5I), a class of medications which now accounts for the largest segment of the ED market. While these drugs are highly efficacious for many men, a relatively large subset of ED patients who do not respond to PDE5I has been identified. Recognition of this subset of the ED population and the ageing of the population has driven researchers to investigate novel treatment targets for ED. Increased research efforts have resulted in the development of several orally available compounds that combine high efficacy with low rates of adverse events. In this review, we address various compounds that regulate penile erection both centrally (Clavulanic acid, Dopamine and Melanocortin receptor agonists) and peripherally (novel PDE5I, soluble and particulate Guanylil Cyclase activators, Rho-kinase inhibitors and Maxi-K channel openers).

Informa Healthcare - Expert Opinion on Emerging Drugs - 0(0):1 - Summary

[Willie]

Hmm...never even heard of some of that stuff. I always like seeing new promising candidates. The more the better, because not all of them get approved.

[Flavio]

Hopefully, Zoraxel (clavulanic acid) will get approved.

I'd love to know what they say about Zoraxel on this study, but I don't want to pay 100 dollars for it (that's the price of the full text of the article). If anyone can find a complete copy on the Internet, please send it to me.